FY2024 Earnings Forecast for GYRE Issued By Noble Financial

Gyre Therapeutics, Inc. (NASDAQ:GYRE) – Noble Financial issued their FY2024 earnings per share (EPS) estimates for Gyre Therapeutics in a research report issued on Tuesday, March 11th. Noble Financial analyst R. Leboyer anticipates that the company will post earnings of $0.17 per share for the year. Noble Financial has a “Outperform” rating on the stock. Noble Financial also issued estimates for Gyre Therapeutics’ Q4 2024 earnings at $0.04 EPS, Q1 2025 earnings at $0.03 EPS, Q2 2025 earnings at $0.03 EPS, Q3 2025 earnings at $0.15 EPS, Q4 2025 earnings at $0.21 EPS, FY2025 earnings at $0.42 EPS, FY2026 earnings at $1.17 EPS, FY2027 earnings at $1.72 EPS and FY2028 earnings at $2.90 EPS.

Gyre Therapeutics Price Performance

Shares of NASDAQ GYRE opened at $11.96 on Thursday. The stock’s 50-day moving average is $11.24 and its 200 day moving average is $12.32. Gyre Therapeutics has a 1-year low of $8.26 and a 1-year high of $19.96.

Institutional Trading of Gyre Therapeutics

Several institutional investors have recently added to or reduced their stakes in the business. Bank of America Corp DE increased its holdings in shares of Gyre Therapeutics by 40.4% in the fourth quarter. Bank of America Corp DE now owns 6,937 shares of the company’s stock worth $84,000 after buying an additional 1,996 shares during the period. Northern Trust Corp grew its position in Gyre Therapeutics by 9.1% during the 4th quarter. Northern Trust Corp now owns 103,382 shares of the company’s stock worth $1,251,000 after acquiring an additional 8,624 shares during the last quarter. Barclays PLC increased its stake in Gyre Therapeutics by 13.5% in the 4th quarter. Barclays PLC now owns 10,543 shares of the company’s stock worth $128,000 after purchasing an additional 1,255 shares during the period. Wells Fargo & Company MN lifted its position in Gyre Therapeutics by 29.4% in the fourth quarter. Wells Fargo & Company MN now owns 4,016 shares of the company’s stock valued at $49,000 after purchasing an additional 913 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its stake in shares of Gyre Therapeutics by 0.8% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 114,566 shares of the company’s stock valued at $1,386,000 after purchasing an additional 918 shares during the period. 23.99% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In related news, President Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock in a transaction on Thursday, December 26th. The shares were sold at an average price of $12.70, for a total value of $25,400.00. Following the transaction, the president now owns 2,928,467 shares in the company, valued at $37,191,530.90. This trade represents a 0.07 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Over the last ninety days, insiders have sold 36,054 shares of company stock valued at $406,537. 19.52% of the stock is currently owned by corporate insiders.

Gyre Therapeutics Company Profile

Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.